| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| 25mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| 250mg |
|
||
| Other Sizes |
|
Purity: ≥98%
PHA-680632 (PHA680632) is a novel and potent pan-aurora kinase inhibitor with potential antitumor activity. It inhibits Aurora A/B/C with IC50s of 27 nM, 135 nM and 120 nM, respectively, and shows 10- to 200-fold higher selectivity for aurora over FGFR1, FLT3, LCK, PLK1, STLK2, and VEGFR2/3. Moreover, PHA 680632 shows potent in vitro antiproliferative activity and high in vivo antitumor efficacy. It potently inhibits proliferation of various cancer cells including HCT116, A2780, HL60 and Hela cells with IC50 values in the nanomolar to micromolar range (0.06 to 7.15 μM).
| ln Vitro |
PHA-680632 exhibits 30- to 200-fold higher IC50 values for FLT3, LCK, PLK1, STLK2, VEGFR2, and VEGFR3 in comparison to Aurora A. Strong antiproliferative action against a variety of cell types is exhibited by PHA-680632. The following have different IC50 values: 0.32, 0.41, 0.06, 1.17, 0.56, 0.62, 0.29, 0.11, 1.56, 0.62, 0.07 for C33A, HeLa, HCT116, HT29, LOVO, A549, MCF7, A2780, U2OS, DU145, U937, HL60, and NHDF. ,0.13,0.41 micrometers. Tumor cells become polyploid due to PHA-680632. Treatment with PHA-680632 cells produces a phenotype resembling Aurora A or B depletion [1]. In certain cancer cell lines, PHA680632 induces polyploidy and inhibits colony formation. Cancer cells respond better to radiation when PHA680632 inhibits Aurora-A, particularly p53-deficient cells [2].
|
||
|---|---|---|---|
| ln Vivo |
In animal studies, PHA-680632 reduces the growth of tumors. When PHA-680632 was administered at a dose of 45 mg/kg in the HL60 human acute myeloid leukemia xenograft model, 85% of TGIs occurred without any severe side effects. PHA-680632 therapy at 60 mg/kg iv for 5 days produced 78% of TGIs without any toxicities in the A2780 human ovarian cancer model [1]. PHA680632 does not function as a radiosensitizer, but it is linked to radiation-associated additive effects in cancer cells, especially in p53-deficient cells [2].
|
||
| Animal Protocol |
|
||
| References |
|
| Molecular Formula |
C28H35N7O2
|
|
|---|---|---|
| Molecular Weight |
501.62
|
|
| Exact Mass |
501.285
|
|
| CAS # |
398493-79-3
|
|
| Related CAS # |
|
|
| PubChem CID |
11249084
|
|
| Appearance |
White to off-white solid powder
|
|
| Density |
1.3±0.1 g/cm3
|
|
| Boiling Point |
709.0±60.0 °C at 760 mmHg
|
|
| Flash Point |
382.6±32.9 °C
|
|
| Vapour Pressure |
0.0±2.3 mmHg at 25°C
|
|
| Index of Refraction |
1.676
|
|
| LogP |
3.04
|
|
| Hydrogen Bond Donor Count |
3
|
|
| Hydrogen Bond Acceptor Count |
5
|
|
| Rotatable Bond Count |
6
|
|
| Heavy Atom Count |
37
|
|
| Complexity |
769
|
|
| Defined Atom Stereocenter Count |
0
|
|
| InChi Key |
OBWNXGOQPLDDPS-UHFFFAOYSA-N
|
|
| InChi Code |
InChI=1S/C28H35N7O2/c1-4-19-7-6-8-20(5-2)25(19)29-28(37)35-17-23-24(18-35)31-32-26(23)30-27(36)21-9-11-22(12-10-21)34-15-13-33(3)14-16-34/h6-12H,4-5,13-18H2,1-3H3,(H,29,37)(H2,30,31,32,36)
|
|
| Chemical Name |
N-(2,6-diethylphenyl)-3-(4-(4-methylpiperazin-1-yl)benzamido)pyrrolo[3,4-c]pyrazole-5(1H,4H,6H)-carboxamide
|
|
| Synonyms |
PHA 680632; PHA-680632; PHA 680632.
|
|
| HS Tariff Code |
2934.99.9001
|
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
|
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
|
|||
|---|---|---|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.08 mg/mL (4.15 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.08 mg/mL (4.15 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.08 mg/mL (4.15 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. Solubility in Formulation 4: 10% Tween 80: 30 mg/mL |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.9935 mL | 9.9677 mL | 19.9354 mL | |
| 5 mM | 0.3987 mL | 1.9935 mL | 3.9871 mL | |
| 10 mM | 0.1994 mL | 0.9968 mL | 1.9935 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Influence of PHA680632 on cell cycle in p53wt vs p53−/− HCT116 cells. Br J Cancer. 2007 Dec 17; 97(12): 1664–1672. |
In vivo tumour growth delay after PHA680632 and irradiation. Br J Cancer, 2007, 97(12), 1664-1672. |
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
COA
